MyD88 and TRIF synergistic interaction is required for TH1-cell polarization with a synthetic TLR4 agonist adjuvant

European Journal of Immunology

Volumn 43, Issue 9, 2013, Pages 2398-2408

  Orr, Mark T ^a   Duthie, Malcolm S ^a   Windish, Hillarie Plessner ^a   Lucas, Elyse A ^a   Guderian, Jeffrey A ^a   Hudson, Thomas E ^a   Shaverdian, Narek ^a   O'Donnell, Joanne ^a   Desbien, Anthony L ^a   Reed, Steven G ^a   Coler, Rhea N ^a,b  

^a INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Adjuvant; CD4+ T cells; GLA; TLR4; Vaccine

Indexed keywords

ADJUVANT; BCG VACCINE; GAMMA INTERFERON; GLUCOPYRANOSYL LIPID ADJUVANT; INTERLEUKIN 2; LIPID EMULSION; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ARTICLE; CD4+ T LYMPHOCYTE; CELL POLARITY; CYTOKINE PRODUCTION; DRUG EFFICACY; EMULSION; IMMUNE RESPONSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TH1 CELL; TUBERCULOSIS;

ADJUVANT; CD4+ T CELLS; GLA; TLR4; VACCINE;

ADAPTOR PROTEINS, VESICULAR TRANSPORT; ADJUVANTS, IMMUNOLOGIC; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; IMMUNIZATION; IMMUNOGLOBULIN CLASS SWITCHING; INTERFERON-GAMMA; INTERLEUKIN-2; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYCOBACTERIUM INFECTIONS; MYCOBACTERIUM TUBERCULOSIS; MYELOID DIFFERENTIATION FACTOR 88; RECEPTORS, IGG; SIGNAL TRANSDUCTION; TH1 CELLS; TOLL-LIKE RECEPTOR 4; TUBERCULOSIS VACCINES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84883543962     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201243124     Document Type: Article

References (31)

1. Lambrecht, B. N., Kool, M., Willart, M. A. and Hammad, H., Mechanism of action of clinically approved adjuvants. Curr. Opin. Immunol. 2009. 21: 23-29.
2. Guy, B., The perfect mix: recent progress in adjuvant research. Nature Rev. Microbiol. 2007. 5: 505-517.
3. Kwissa, M., Kasturi, S. P. and Pulendran, B., The science of adjuvants. Expert Rev. Vaccines 2007. 6: 673-684.
4. Casella, C. R. and Mitchell, T. C., Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant. Cell Mol. Life Sci. 2008. 65: 3231-3240.
5. Cluff, C. W., Monophosphoryl lipid A (MPL) as an adjuvant for anti-cancer vaccines: clinical results. Adv. Exp. Med. Biol. 2010. 667: 111-123.
6. Anderson, R. C., Fox, C. B., Dutill, T. S., Shaverdian, N., Evers, T. L., Poshusta, G. R., Chesko, J. et al., Physicochemical characterization and biological activity of synthetic TLR4 agonist formulations. Coll. Surf. B Biointerf. 2010. 75: 123-132.
7. Baldwin, S. L., Bertholet, S., Kahn, M., Zharkikh, I., Ireton, G. C., Vedvick, T. S., Reed, S. G. et al., Intradermal immunization improves protective efficacy of a novel TB vaccine candidate. Vaccine 2009. 27: 3063-3071.
8. Baldwin, S. L., Shaverdian, N., Goto, Y., Duthie, M. S., Raman, V. S., Evers, T., Mompoint, F. et al., Enhanced humoral and type 1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion. Vaccine 2009. 27: 5956-5963.
9. Raman, V. S., Bhatia, A., Picone, A., Whittle, J., Bailor, H. R., O'Donnell, J., Pattabhi, S. et al., Applying TLR synergy in immunotherapy: implications in cutaneous leishmaniasis. J. Immunol. 2010. 185: 1701-1710.
10. Raman, V. S., O'Donnell, J., Bailor, H. R., Goto, W., Lahiri, R., Gillis, T. P., Reed, S. G. et al., Vaccination with the ML0276 antigen reduces local inflammation but not bacterial burden during experimental Mycobacterium leprae infection. Infection Immunity 2009. 77: 5623-5630.
11. Bertholet, S., Ireton, G. C., Ordway, D. J., Windish, H. P., Pine, S. O., Kahn, M., Phan, T. et al., A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis. Sci. Trans. Med. 2010. 2: 53ra74.
12. Coler, R. N., Bertholet, S., Moutaftsi, M., Guderian, J. A., Windish, H. P., Baldwin, S. L., Laughlin, E. M. et al., Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant. PloS One 2011. 6: e16333.
13. Pantel, A., Cheong, C., Dandamudi, D., Shrestha, E., Mehandru, S., Brane, L., Ruane, D. et al., A new synthetic TLR4 agonist, GLA, allows dendritic cells targeted with antigen to elicit Th1 T-cell immunity in vivo. Eur. J. Immunol. 2012. 42: 101-109.
14. Windish, H. P., Duthie, M. S., Ireton, G., Lucas, E., Laurance, J. D., Bailor, R. H., Coler, R. N. et al., Protection of mice from Mycobacterium tuberculosis by ID87/GLA-SE, a novel tuberculosis subunit vaccine candidate. Vaccine 2011. 29: 7842-7848.
15. Baldwin, S. L., Bertholet, S., Reese, V. A., Ching, L. K., Reed, S. G. and Coler, R. N., The importance of adjuvant formulation in the development of a tuberculosis vaccine. J. Immunol. 2012. 188: 2189-2197.
16. Oshiumi, H., Matsumoto, M., Funami, K., Akazawa, T. and Seya, T., TICAM-1, an adaptor molecule that participates in toll-like receptor 3-mediated interferon-beta induction. Nature Immunol. 2003. 4: 161-167.
17. Coler, R. N., Baldwin, S. L., Shaverdian, N., Bertholet, S., Reed, S. J., Raman, V. S., Lu, X. et al., A synthetic adjuvant to enhance and expand immune responses to influenza vaccines. PloS One 2010. 5: e13677.
18. Mata-Haro, V., Cekic, C., Martin, M., Chilton, P. M., Casella, C. R. and Mitchell, T. C., The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science 2007. 316: 1628-1632.
19. Cekic, C., Casella, C. R., Eaves, C. A., Matsuzawa, A., Ichijo, H. and Mitchell, T. C., Selective activation of the p38 MAPK pathway by synthetic monophosphoryl lipid A. J. Biol. Chem. 2009. 284: 31982-31991.
20. Persing, D. H., Coler, R. N., Lacy, M. J., Johnson, D. A., Baldridge, J. R., Hershberg, R. M. and Reed, S. G., Taking toll: lipid A mimetics as adjuvants and immunomodulators. Trends Microbiol. 2002. 10: S32-S37.
21. Shen, H., Tesar, B. M., Walker, W. E. and Goldstein, D. R., Dual signaling of MyD88 and TRIF is critical for maximal TLR4-induced dendritic cell maturation. J. Immunol. 2008. 181: 1849-1858.
22. Lambert, S. L., Yang, C. F., Liu, Z., Sweetwood, R., Zhao, J., Cheng, L., Jin, H. et al., Molecular and cellular response profiles induced by the TLR4 agonist-based adjuvant Glucopyranosyl Lipid A. PloS One 2012. 7: e51618.
23. Rhee, E. G., Kelley, R. P., Agarwal, I., Lynch, D. M., La Porte, A., Simmons, N. L., Clark, S. L. et al., TLR4 ligands augment antigen-specific CD8+ T lymphocyte responses elicited by a viral vaccine vector. J. Virol. 2010. 84: 10413-10419.
24. Fremond, C. M., Yeremeev, V., Nicolle, D. M., Jacobs, M., Quesniaux, V. F. and Ryffel, B., Fatal Mycobacterium tuberculosis infection despite adaptive immune response in the absence of MyD88. J. Clin. Invest. 2004. 114: 1790-1799.
25. Scanga, C. A., Bafica, A., Feng, C. G., Cheever, A. W., Hieny, S. and Sher, A., MyD88-deficient mice display a profound loss in resistance to Mycobacterium tuberculosis associated with partially impaired Th1 cytokine and nitric oxide synthase 2 expression. Infection Immunity 2004. 72: 2400-2404.
26. Bowen, W. S., Minns, L. A., Johnson, D. A., Mitchell, T. C., Hutton, M. M. and Evans, J. T., Selective TRIF-dependent signaling by a synthetic toll-like receptor 4 agonist. Sci. Signal. 2012. 5: ra13.
27. Clegg, C. H., Roque, R., Van Hoeven, N., Perrone, L., Baldwin, S. L., Rininger, J. A., Bowen, R. A. et al., Adjuvant solution for pandemic influenza vaccine production. Proc. Natl. Acad. Sci. U.S.A. 2012. 109: 17585-17590.
28. O'Neill, L. A. and Bowie, A. G., The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nature Rev. Immunol. 2007. 7: 353-364.
29. Badovinac, V. P., Haring, J. S. and Harty, J. T., Initial T-cell receptor transgenic cell precursor frequency dictates critical aspects of the CD8(+) T-cell response to infection. Immunity 2007. 26: 827-841.
30. Thompson, B. S., Chilton, P. M., Ward, J. R., Evans, J. T. and Mitchell, T. C., The low-toxicity versions of LPS, MPL adjuvant and RC529, are efficient adjuvants for CD4+ T cells. J. Leukocyte Biol. 2005. 78: 1273-1280.
31. Hajjar, A. M., Ernst, R. K., Fortuno, E. S., 3rd, Brasfield, A. S., Yam, C. S., Newlon, L. A., Kollmann, T. R. et al., Humanized TLR4/MD-2 mice reveal LPS recognition differentially impacts susceptibility to Yersinia pestis and Salmonella enterica. PLoS Pathogens 2012. 8: e1002963.